Task: Answer Verification
Input (English): Question: Does addition of rituximab to chop increase the risk of cardiotoxicity in patients with non-Hodgkin 's lymphoma?
Answer: Both CHOP and R-CHOP cause diastolic dysfunction in the early period following their administration. The addition of rituximab to CHOP chemotherapy does not significantly increase the risk of doxorubicin-induced cardiotoxicity during this period.
Output (English): no